Golden
Indee Labs

Indee Labs

Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.

Indee Labs was founded in August 2015 with a 'mission to democratize gene-modified cell therapies' such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein and/or various complexes) to human primary immune cells in seconds.



Microfluidic Vortex Shedding

The core technology, microfluidic vortex shedding (µVS), uses a microscopic fluid dynamics phenomenon based on vortex shedding to hydrodynamically porate the cell membrane allowing for the deliberate introduction of genetic material to human primary immune cells. Vortex shedding is not a new phenomenon. It can be observed as water flows past boulders in rivers while also being seen as clouds drift over mountains.



µVS is not the only transfection technology, however, it is shown to be able to rapidly deliver a range of genetic material to human primary immune cells with high cell recovery, high cell viability and high efficiency and high throughput. Furthermore, µVS results in negligible perturbation of immune cell proliferation, activation, exhaustion, phenotype, function nor transcriptome-wide gene expression. µVS is also induced with a 5 mm x 10 mm microfluidic device manufactured using industry-standard semiconductor processes. Cumulatively, this means µVS is an extremely scalable, gentle and robust alternative to incumbent technologies such as viral transduction and electroporation.



Funding

As of May 2018, Indee Labs had accumulated more than USD$6.1 million dollars in angel, venture and non-dilutive capital.



Angel

In July 2017, Indee Labs closed USD$1.3M in accelerator and angel financing from SOSV, IndieBio, Jude Gomila, Shaun Maguire, Y Combinator and Jaffray Woodriff (executed by his family office, Felton Group, LLC) among others.



Seed

In May 2018, Indee Labs closed out a seed round resulting in USD$2.6M in angel and venture financing from Founders Fund, Main Sequence Ventures, Social+Capital also among others.



Non-dilutive Funding

Award
Funding Agency
Value
Year
Link

BioMedTech Horizons Precision Medicine

MTP Connect

AUD$891,500

2018-20

Minimum Viable Product

Jobs for NSW

AUD$15,000

2016

Overseas Finding

AusIndustry

AUD$502,050

2016-18



Timeline

February 1, 2018

Indee Labs presents at MF-9

Indee Labs presents at MF-9, the Ninth Microfluidics Consortium.

January 24, 2018

Indee Labs featured by Main Sequence Ventures





January 8, 2018

Indee Labs mentioned by the Australian Trade and Investment Commission.

Indee Labs mentioned by the Australian Trade and Investment Commission.

December 7, 2017

Indee Labs selected for the Wilson Sonsini Goodrich & Rosati Healthcare Innovations Venture Investment Forum.

Indee Labs selected for the Wilson Sonsini Goodrich & Rosati Healthcare Innovations Venture Investment Forum.

November 15, 2017

Indee Labs featured by Eagar & Martin Patent & Trademark Attorneys.

Indee Labs featured by Eagar & Martin Patent & Trademark Attorneys.

October 4, 2017

Lightning Talk at Synbiobeta

Amy Twite presents a Lightning Talk at Synbiobeta.

July 3, 2017

Indee Labs closes $1.3M Angel Round

Indee Labs closes $1.3M Angel Round.

May 24, 2017

Indee Labs selected to present at Australian-American Enabling Technologies Meeting.

Indee Labs selected to present at Australian-American Enabling Technologies Meeting.

March 20, 2017

Indee Labs launches at Y Combinator’s Winter 2017 Demo Day.

Indee Labs launches at Y Combinator’s Winter 2017 Demo Day.

People

Name
Role
Related Golden topics

Adrian Lievano

Bioengineer



Christian Meyers

Investor



Courtney Broadus

Investor



Dylan Flood

Investor



Jay Zaveri

Investor



Jeff Chang

Investor



John Moyer

Investor



Jude Gomila

Investor



Julyana Acevado, PhD

Scientist



Justin Jarrell, PhD

Scientist



Katherine Lau

Bioengineer



Rob McInnes

Investor



Ryan Flynn

Investor



Ryan Pawell

CEO



Shaun Maguire

Investor



Warren McKenzie, PhD

CEO, Australia



Further reading

Title
Author
Link
Type
Date

Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding

Amy A. Twite, Katherine H.W.J. Lau, Moein N. Kashani, Craig Priest, Jorge Nieva, David Gottlieb, Ryan S. Pawell

Pre-print



Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding

Justin A. Jarrell, Amy A. Twite, Katherine H. W. J. Lau, Moein N. Kashani, Adrian A. Lievano, Julyana Acevedo, Craig Priest, Jorge Nieva, David Gottlieb & Ryan S. Pawell

Nature Scientific Reports



Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References